Difference between revisions of "Part:BBa K4960034"
(→Profile) |
|||
(21 intermediate revisions by 4 users not shown) | |||
Line 4: | Line 4: | ||
Structural and accessory genes | Structural and accessory genes | ||
− | + | ===Profile=== | |
+ | Name:pvc1-pvc12,pvc13_NTD-2*Bsal-pVc13_CTD,pvc14-pvc16<br> | ||
+ | Base Pairs: 19822bp<br> | ||
+ | Origin: <i>Photorhabdus</i><br> | ||
+ | Properties: Structural and accessory genes<br> | ||
<!-- Add more about the biology of this part here--> | <!-- Add more about the biology of this part here--> | ||
+ | |||
===Usage and Biology=== | ===Usage and Biology=== | ||
This part is necessary for the assembly of a functional injection system. PVCs probably recognize target cells via tail fibres (Pvc13), leading to a contraction of the sheath mechanism that drives a spike through the cellular membrane.[1]<br> | This part is necessary for the assembly of a functional injection system. PVCs probably recognize target cells via tail fibres (Pvc13), leading to a contraction of the sheath mechanism that drives a spike through the cellular membrane.[1]<br> | ||
− | Pvc2, Pvc3 and Pvc4 compose the sheath of PVC. Pvc16 is sheath terminator of PVC. Pvc13 is tail fibres of PVC. Pvc9, Pvc11 and Pvc12 compose the baseplate of PVC. Pvc8 and Pvc10 compose the spike of PVC. Pvc1, Pvc5 and Pvc7 compose the tube of PVC.[2]<br> | + | Pvc2, Pvc3 and Pvc4 compose the sheath of PVC. Pvc16 is sheath terminator of PVC. Pvc13 is tail fibres of PVC. Pvc9, Pvc11 and Pvc12 compose the baseplate of PVC. Pvc8 and Pvc10 compose the spike of PVC. Pvc1, Pvc5 and Pvc7 compose the tube of PVC.[2]('''Fig.1''')<br> |
− | This part has a Bsal enzyme recognizing sequence, which can allow to use the way Golden Gate Assembly to construct a plasmid. | + | This part has a Bsal enzyme recognizing sequence, which can allow to use the way Golden Gate Assembly to construct a plasmid.('''Fig.2''') |
+ | <html> | ||
+ | |||
+ | <figure class="figure"> | ||
+ | <img src="https://static.igem.wiki/teams/4960/wiki/composite-part/bsal-replace/beautiful-pvc.png" height="120px"> | ||
+ | |||
+ | </figure> | ||
+ | |||
+ | </html> | ||
+ | '''Figure 1.PVC composition diagram'''<br> | ||
+ | |||
<html> | <html> | ||
<figure class="figure"> | <figure class="figure"> | ||
− | <img src="https://static.igem.wiki/teams/4960/wiki/ | + | <img src="https://static.igem.wiki/teams/4960/wiki/golden-gate.jpg" height="650px"> |
</figure> | </figure> | ||
</html> | </html> | ||
− | Figure | + | '''Figure 2 AlphaFold2-guided Design of Adipose Cell-targeting PVC Coat Expressing Plasmids.''' (a) AlphaFold2 based prediction of engineered PVC tail fiber trimer structure. Structure of adipose-targeting CKGGRAKDC peptide-presenting PVC tail fiber with indicated linkers were shown. (b) Schematic diagram of the newly-designed pvc13 part allowing Golden Gate cloning of targeted sequence into the pPVC plasmid.<br> |
===Special Design=== | ===Special Design=== | ||
− | + | To enable the PVC-based delivery of UCP1 into white adipose tissue, we then decided to equip the tail fiber protein of PVC (PVC13) with an adipose tissue-targeting 9-mer peptide developed by Kolonin et al. in 2004[3]. To ensure the efficient exposure of the targeting peptide on the tail fiber, we predicted the structure of PVC13 trimers inserted with adipose tissue targeting peptide flanked by different linkers (Figure 2a). We were unable to peruse validating these constructs due to the limited time before the jamboree and the practical difficulties in working with such a huge plasmid (~25kb), while we did make some effort in simplifying the cloning process by designing a new PVC13 part which allows subsequent Golden-gate-based cloning of the targeting sequence into the pPVC plasmid (Figure 2b, see the second part of our Engineering page for more information).<br> | |
<!-- --> | <!-- --> | ||
===Sequence and Features=== | ===Sequence and Features=== | ||
Line 40: | Line 55: | ||
<!-- --> | <!-- --> | ||
===References=== | ===References=== | ||
− | [1] | + | [1] J. Kreitz et al., “Programmable protein delivery with a bacterial contractile injection system,” Nature, vol. 616, no. 7956, pp. 357–364, Apr. 2023.<br> |
− | [2]Kolonin | + | [2] F. Jiang et al., “Cryo-EM Structure and Assembly of an Extracellular Contractile Injection System,” Cell, vol. 177, no. 2, pp. 370-383.e15, Apr. 2019,.<br> |
+ | [3]Kolonin, M. G., Saha, P. K., Chan, L., Pasqualini, R., & Arap, W. (2004). Reversal of obesity by targeted ablation of adipose tissue. Nat Med, 10(6), 625-632. https://doi.org/10.1038/nm1048 |
Latest revision as of 14:34, 12 October 2023
pPVC promoter->pvc1-pvc12->pvc13_NTD-2*Bsal-pVc13_CTD->pvc14-pvc16
Structural and accessory genes
Profile
Name:pvc1-pvc12,pvc13_NTD-2*Bsal-pVc13_CTD,pvc14-pvc16
Base Pairs: 19822bp
Origin: Photorhabdus
Properties: Structural and accessory genes
Usage and Biology
This part is necessary for the assembly of a functional injection system. PVCs probably recognize target cells via tail fibres (Pvc13), leading to a contraction of the sheath mechanism that drives a spike through the cellular membrane.[1]
Pvc2, Pvc3 and Pvc4 compose the sheath of PVC. Pvc16 is sheath terminator of PVC. Pvc13 is tail fibres of PVC. Pvc9, Pvc11 and Pvc12 compose the baseplate of PVC. Pvc8 and Pvc10 compose the spike of PVC. Pvc1, Pvc5 and Pvc7 compose the tube of PVC.[2](Fig.1)
This part has a Bsal enzyme recognizing sequence, which can allow to use the way Golden Gate Assembly to construct a plasmid.(Fig.2)
Figure 1.PVC composition diagram
Figure 2 AlphaFold2-guided Design of Adipose Cell-targeting PVC Coat Expressing Plasmids. (a) AlphaFold2 based prediction of engineered PVC tail fiber trimer structure. Structure of adipose-targeting CKGGRAKDC peptide-presenting PVC tail fiber with indicated linkers were shown. (b) Schematic diagram of the newly-designed pvc13 part allowing Golden Gate cloning of targeted sequence into the pPVC plasmid.
Special Design
To enable the PVC-based delivery of UCP1 into white adipose tissue, we then decided to equip the tail fiber protein of PVC (PVC13) with an adipose tissue-targeting 9-mer peptide developed by Kolonin et al. in 2004[3]. To ensure the efficient exposure of the targeting peptide on the tail fiber, we predicted the structure of PVC13 trimers inserted with adipose tissue targeting peptide flanked by different linkers (Figure 2a). We were unable to peruse validating these constructs due to the limited time before the jamboree and the practical difficulties in working with such a huge plasmid (~25kb), while we did make some effort in simplifying the cloning process by designing a new PVC13 part which allows subsequent Golden-gate-based cloning of the targeting sequence into the pPVC plasmid (Figure 2b, see the second part of our Engineering page for more information).
Sequence and Features
Tube:pvc1, pvc5, pvc7
Sheath:pvc2, pvc3, pvc4
Sheath terminator:pvc15
Tail fbres:pvc13_NTD-2*Bsal-pVc13_CTD
Baseplate:pvc9, pvc11, pvc12
Spike:pvc8, pvc10
Assembly method:3A Assembly
- 10COMPATIBLE WITH RFC[10]
- 12INCOMPATIBLE WITH RFC[12]Illegal NheI site found at 7406
- 21INCOMPATIBLE WITH RFC[21]Illegal BglII site found at 2407
Illegal BglII site found at 11264
Illegal BglII site found at 14099
Illegal BglII site found at 16930
Illegal XhoI site found at 2691 - 23COMPATIBLE WITH RFC[23]
- 25INCOMPATIBLE WITH RFC[25]Illegal NgoMIV site found at 11792
Illegal NgoMIV site found at 17461
Illegal NgoMIV site found at 17600
Illegal AgeI site found at 6704
Illegal AgeI site found at 9641
Illegal AgeI site found at 10327
Illegal AgeI site found at 10468
Illegal AgeI site found at 11576
Illegal AgeI site found at 17899
Illegal AgeI site found at 19587 - 1000COMPATIBLE WITH RFC[1000]
References
[1] J. Kreitz et al., “Programmable protein delivery with a bacterial contractile injection system,” Nature, vol. 616, no. 7956, pp. 357–364, Apr. 2023.
[2] F. Jiang et al., “Cryo-EM Structure and Assembly of an Extracellular Contractile Injection System,” Cell, vol. 177, no. 2, pp. 370-383.e15, Apr. 2019,.
[3]Kolonin, M. G., Saha, P. K., Chan, L., Pasqualini, R., & Arap, W. (2004). Reversal of obesity by targeted ablation of adipose tissue. Nat Med, 10(6), 625-632. https://doi.org/10.1038/nm1048